WestVac Biopharma网站基础信息介绍

网站域名：westvacpharma.com

官方标题：WestVac Biopharma

网页Meta关键词：成都威斯克生物医药有限公司，威斯克生物，威斯克，四川大学华西--，四川大学生物治疗国家重点实验室，魏于全，生物医药，传染性疾病，恶性肿瘤，mRNA疫苗，新冠病毒，肺炎，疫苗，昆虫细胞，重组蛋白，重组蛋白疫苗，免疫治疗

页面描述：WestVac Biopharma is founded by Academician Wei Yuquan from West China Hospital of Sichuan University, together with 10 scientists from State Key Laboratory of Biotherapy(SKLB). Its headquarter is located in the International Bio-Town, Chengdu. The CEO of WestVac Biopharma is Prof.Wei Yuquan, who is the Academician of Chinese Academy of Sciences as well as the Director of State Key Laboratory of Biotherapy.WestVac is committed to exploring the latest biotherapy technologies for major diseases, including infectious diseases, malignant tumors, cardio**scular diseases, and so on. It has attached great importance in the Research and Development(R&D) of COVID-19 **ccine especially and building a COVID-19 **ccine production platform. State Key Laboratory of Biotherapy (SKLB) was established by the Ministry of Sciences and Technology of China in 2005 and became one of the National R&D Platforms for Novel Drugs founded by the Ministries of Sciences and Technology as well as that of Health of China in 2008. It is also supported by National Collaborative Inno**tion Program and has become the National Collaborative Inno**tion Center for Biotherapy since 2013.West China Hospital of Sichuan University，founded in 1892, is the National Center for Diagnosis and Treatment of Severe and Critical Diseases in Western China. It is also the world’s largest comprehensive hospital complex located in one campus area.Relying on the medical resources of State Key Laboratory of Biotherapy and West China Medical Center, WestVac has adopted recombinant protein methodology to develop the COVID-19 **ccine. Because of the safety of the protein **ccine , it is also the only COVID-19 **ccine approved for the use in children over 3 years old in China.The **ccine was approved by the National Medical Products Administration for clinical trials on August 21,2020. Phase I/II clinical trials have been completed, and phase III clinical trials are being carried out in Nepal, Kenya, Japan and other countries.The **ccine targets the spike protein binding domain (S-RBD) of SARS-CoV-2, producing neutralizing antibodies to block COVID-19 infection of human cells. The result was published on Nature, the world’s famous scientific journal on July 29th, 2020. It has also been the first paper of COVID **ccine published by Nature since the pandemic outbreak. The S-RBD gene of the COVID-19 virus is introduced into the insect cells, which were used as a factory to produce high-quality recombinant **ccine protein and then does refined purification. Such technology is easy to be mass-produced and brought to the market.WestVac Biopharma is committed to becoming the world`s leading **ccine and immunotherapy platform.

WestVac Biopharma流量与权重数据分析

百度PC流量：62 ~ 87

百度移动流量：当前站点移动搜索流量较低

百度权重：0

移动权重：1

搜狗权重：0

360权重：0

Bing权重：0

预估日均IP：当前站点流量较少

WestVac Biopharma百度PC关键词排名

百度移动关键词排名

搜索引擎收录情况

百度收录：-

360收录：-

搜狗收录：-

备案与域名信息

域名年龄：域名年龄：5年2月27日 注册时间：创建于2021年03月09日

服务器环境信息

协议：HTTP/1.1 200 OK

页面类型：text/html; charset=utf-8

服务器：Microsoft-IIS/10.0

程序支持：ASP.NET

GZIP：已启用GZIP压缩

子域名信息

子域名总数：2